Breaking Down Axsome Therapeutics: 19 Analysts Share Their Views
Axsome Therapeutics Is Maintained at Outperform by RBC Capital
RBC Lifts Price Target on Axsome Therapeutics to $131 From $130, Keeps Outperform Rating
The Five-year Returns Have Been Enviable for Axsome Therapeutics (NASDAQ:AXSM) Shareholders Despite Underlying Losses Increasing
Express News | Axsome Therapeutics: Fifth Amendment to Increase Tranche 3 Commitment From $75 to $80 Mln
Express News | Axsome Therapeutics: On September 30 Entered Into Fifth Amendment to Its Loan & Security Agreement Dated Sept 25, 2020
Wells Fargo Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $140
Axsome Therapeutics Added to Q4 2024 Tactical Ideas List at Wells Fargo
Buy Rating Justified for Axsome Therapeutics Amidst Strong Market Opportunities and Promising Trial Outcomes
Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (ESTA), Alkermes (ALKS) and Axsome Therapeutics (AXSM)
Axsome Therapeutics Presents Data From Multiple Programs at Sleep Europe 2024
Axsome Therapeutics: A Strong Buy on Auvelity's Robust Market Performance and Growth Prospects
RBC Capital Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $130
TD Cowen Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $120
Axsome Therapeutics Insider Sold Shares Worth $1,005,871, According to a Recent SEC Filing
Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $106
Analysts Expect Breakeven For Axsome Therapeutics, Inc. (NASDAQ:AXSM) Before Long
Axsome Therapeutics (AXSM) Gets a Buy From Cantor Fitzgerald
Needham Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $130